Novo Nordisk (NVO)
(Delayed Data from NYSE)
$126.73 USD
-1.13 (-0.88%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $126.89 +0.16 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
NVO 126.73 -1.13(-0.88%)
Will NVO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Is Eli Lilly's Stock in a Bubble?
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Other News for NVO
Novo Nordisk’s ($NVO) Wegovy Gets EU Support to Expand Its Use
FDA warns of possible overdoses with compounded semaglutide injections
Hims & Hers lower after FDA warns of dosing errors with Ozempic
Novo Nordisk: Better Buying Opportunities Ahead
Artisan Global Opportunities Fund Q2 2024 Commentary